期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

蛋白质二硫键异构酶在心血管疾病中作用机制的研究进展

Protein disulfide isomerase's role in cardiovascular disease
下载PDF
导出
摘要 蛋白质二硫键异构酶是一种主要存在于内质网中的巯基-二硫键氧化还原酶。已经证实其具有催化二硫键形成及重排、调节蛋白质的折叠等多种生物学功能,现发现该蛋白也可作为一个潜在的心血管疾病生物学标志物,在急性心肌梗死中可以减少梗死面积和凋亡心肌细胞数目;在糖尿病心肌病中,能降低心肌易损性;在高血压和血栓形成过程中也担任着一个重要的角色。因此,本文主要针对蛋白质二硫键异构酶在心血管疾病发生发展中的机制研究进展予以综述。 Protein disulfide isomerase （PDI） is one of thiol-disulfide oxidoreductases that mainly located in the endo？plasmic reticulum （ER）. It is generally known that PDI caralyzes the formation,rearrangement,breakage of disulfide bonds, and this enzyme is effective in regulation of protein folding. Now it is also known as a biomarker of cardiovascular disease. Protein disulfide isomerase can reduce infarct size and myocardial apoptosis in acute myocardial infarction （AMI）. PDI can also improve changes of cardiac vulnerability in diabetic cardiomyopathy （DCM）. Further more, it is also shown that PDI play an important role in hypertension and thrombosis. Therefore, this paper review the effects of protein disulfide isomerase in cardiovascular diseases.
作者 盛梦婷 黄子芮 潘黎明 李俊明
机构地区 三峡大学人民医院 宜昌市第一人民医院
出处 《天津医药》 CAS 2015年第10期1205-1208,共4页 Tianjin Medical Journal
基金 国家自然科学基金资助项目(81270280)
关键词 蛋白质二硫化物异构酶 心肌梗死 糖尿病并发症 心肌疾病 高血压 血栓形成 综述 protein disulfide-isomerase myocardial infarction diabetes complications cardiomyopathies hypertension thrombosis review
分类号 R541 [医药卫生—心血管疾病]
  • 相关文献

参考文献33

  • 1Yoshioka J. Thioredoxin superfamily and its effects on cardiac phys- iology and pathology[J]. Compr Physiol, 2015, 5(2): 513-530. doi: 10.1002/cphy.c 140042.
  • 2Goldberger RF, Epstein C J, Anfeinsen CB. Acceleration of reactiva- tion of reduced bovine pancreatic ribonuclease by a microsomal sys- tem from rat liver[J]. J Biol Chem, 1963, 238: 628-635.
  • 3Venetianer P, Straub FB. Enzymic formation of the disulfide bridges of ribonuclease[J]. Acta Physiol Acad Sci Hung, 1963, 24:41-53.
  • 4Givol D, Goldberger RF, Anfinsen CB. Oxidation and disulfide in-terchange in the reactivation of reduced ribonuclease[J]. J Biol Chem, 1964, 239:PC3114-3116.
  • 5All Khan H, Mutus B. Protein disulfide isomerase a muhifunctional protein with multiple physiological roles[J]. Front Chem, 2014, 2: 70. doi: 10.3389/fchem. 2014.00070. eCollection 2014.
  • 6Conway ME, Harris M. S-nitmsylation of thr thioredoxin-like do- mains of protein disulfide isomerase and tis role in neurodegenera- tire conditions[J]. Front Chem, 2015, 3:27. doi: 10.1089/ ars.2012.4630.
  • 7Wang C, Li W, Ren J, et al. Structural insights into the redox-regu- lated dynamic conformations of human protein disulfide isomerase [J]. Antioxid Redox Signal, 2013, 19(1): 36-45. doi: 10.1089/ ars.2012.4630.
  • 8Wang C, Yu J, Huo L, et al. Human protein-disulfide isomerase is a redox-regulated chaperone activated by oxidation of domain a'[J]. J Biol Chem, 2012, 287(2): 1139-1149. doi: 10.1074/jbc.M111.303149.
  • 9Hotamisligil GS. Endoplasmie retieulum stress and the inflammato- ry basis of metabolic disease[J]. Cell, 2010 , 140(6): 900-917. doi: 10.1016/j.cell.2010.02.034.
  • 10Wang WB, Shi Q, Xu Y, et al. Protein disulfide isomerase regulates endoplasmic reticul.um stress and the apoptotic process during pri- on infection and PrP mutant-induced cytotoxicity[J]. PLoS One, 2012, 7(6): e38221, doi: 10.1371/journal.pone.0038221.

二级参考文献13

  • 1Malyszko J,Tymcio J.Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension[J].Pol Arch Med Wewn,2008,118(1-2):36-41.
  • 2Spiel AO,Gilbert JC,Jilma B.Yon willebrand factor in cardiovascular disease:focus on acute coronary syndromes[J].Circulation,2008,117(11):1449-1459.
  • 3Guthold M,Liu W,Sparks EA,et al.A comparison of the mechanical and structural properties of fibrin fibers with other protein fibers[J].Cell Biochem Biophys,2007,49(3):165-181.
  • 4Corrado E,Rizzo M,Coppola G,et al.An update on the role of markers of inflammation in atherosclerosis[J].J Atheroscler Thromb,2010,17(1):1-11.
  • 5Tabak O,Gelisgen R,Uzun H,et al.Hypertension and hemostatic/fibrinolytic balance disorders[J].Clin Invest Med,2009,32(6):E285-E292.
  • 6Guardado-mendoza R,Jimenez-ceja L,Pacheco-carrasco MF,et al.Fibrinogen is associated with silent myocardial ischaemia in type 2 diabetes mellitus[J].Acta Cardiol,2009,64(4):523-530.
  • 7Oliver JJ,Webb DJ,Newby DE.Stimulated tissue plasminogen activator release as a marker of endcthelial function in humans[J].Arterioscler Thromb Vasc Biol,2005,25(12):2470-2479.
  • 8Remková A,Kratochvíl'ová H,Durina J.Impact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension[J].J Hum Hypertens,2008,22(5):338-345.
  • 9Brown NJ.Blood pressure reduction and tissue-type plasminogen activator release[J].Hypertension,2006,47(4):648-649.
  • 10Giannarelli C,Virdis A,De NF,et al.Tissue-type plasminogen activator release in healthy subjects and hypertensive patients:relationship with beta-adrenergic receptors and the nitric oxide pathway[J].Hypertension,2008,52(2):314-321.

共引文献3

天津医药
2015年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部